Chongqing Zhifei Biological Products Co., Ltd. (SHE:300122)

Market Cap	56.78B
Revenue (ttm)	17.05B
Net Income (ttm)	255.59M
Shares Out	2.39B
EPS (ttm)	0.11
PE Ratio	222.28
Forward PE	39.23
Dividend	0.20 (0.86%)
Ex-Dividend Date	Dec 25, 2024

Volume	44,654,583
Average Volume	59,526,293
Open	23.29
Previous Close	23.72
Day's Range	22.85 - 23.79
52-Week Range	18.70 - 40.43
Beta	0.72
RSI	60.75
Earnings Date	Aug 19, 2025

About SHE:300122

Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal Polysaccharide Vaccine under the Menwayc brand; Mycobacterium Vaccae for Injection under the Vaccae brand; Meningococcal Group A and Group C Polysacchar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 7,220
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300122

Financial Performance

In 2024, SHE:300122's revenue was 26.07 billion, a decrease of -50.74% compared to the previous year's 52.92 billion. Earnings were 2.02 billion, a decrease of -74.99%.